Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 +1.87%84 Return-on-Tangible-Asset is 0.08% as of Mar. 2026, which is 99% below its 10-year median of 10.06. GuruFocus rates SHSE:688656 with a GF Score™ of 84/100 and a GF Value™ of ¥90.36 (Fairly Valued). The stock has 8 warning signs investors should review. Among 855 Medical Devices & Instruments companies, HOB Biotech Group ranks better than 56.02% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. HOB Biotech Group's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥0.7 Mil. HOB Biotech Group's average total tangible assets for the quarter that ended in Mar. 2026 was ¥911.1 Mil. Therefore, HOB Biotech Group's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.08%.
The historical rank and industry rank for HOB Biotech Group's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688656'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.29 Med: 10.06 Max: 25.73
Current: 2.29
During the past 10 years, HOB Biotech Group's highest Return-on-Tangible-Asset was 25.73%. The lowest was 2.29%. And the median was 10.06%.
SHSE:688656's Return-on-Tangible-Asset is ranked better than 56.02% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs SHSE:688656: 2.29
HOB Biotech Group (SHSE:688656) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
HOB Biotech Group Return-on-Tangible-Asset Related Terms
HOB Biotech Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, HOB Biotech Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.08% mean?
HOB Biotech Group (SHSE:688656) has a Return-on-Tangible-Asset of 0.08% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on HOB Biotech Group and its competitors. This is 99% below median its historical median of 10.06. Over the past decade, HOB Biotech Group's Return-on-Tangible-Asset has ranged from 2.29 to 25.73. According to the industry distribution chart, HOB Biotech Group ranks #376 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 44%.
Is HOB Biotech Group's Return-on-Tangible-Asset too high?
HOB Biotech Group's current Return-on-Tangible-Asset of 0.08% is 99% below median its 10-year median of 10.06. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 25.73. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.56. HOB Biotech Group's value of 0.08% is 85.7% below this industry median. Based on the distribution chart, HOB Biotech Group ranks #376 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, HOB Biotech Group has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #376 out of 855 companies for Return-on-Tangible-Asset. This puts HOB Biotech Group in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.56. HOB Biotech Group's value of 0.08% is 85.7% below this benchmark. Historically, HOB Biotech Group's own Return-on-Tangible-Asset has ranged from 2.29 to 25.73 over the past decade. While the company's 10-year median is 10.06 vs. the industry median of 0.56, HOB Biotech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.56, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Return-on-Tangible-Asset of 0.08% is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Return-on-Tangible-Asset is 0.08%, which is 99% below median its own 10-year median of 10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Fairly Valued. The stock's GF Value™ is ¥90.36, compared to a current price of ¥87.03 — trading 3.7% below its estimated fair value. The current Return-on-Tangible-Asset is 0.08%, which is 99% below median its 10-year median of 10.06 and 85.7% below the Medical Devices & Instruments industry median of 0.56. HOB Biotech Group's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Return-on-Tangible-Asset is 0.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥87.03 is trading 3.7% below its estimated GF Value™ of ¥90.36.
GuruFocus considers HOB Biotech Group to be Fairly Valued.
Key valuation signals for SHSE:688656:
Return-on-Tangible-Asset: 0.08% (99% below median its 10-year median of 10.06)
GF Value™: ¥90.36 vs. price of ¥87.03 (3.7% below fair value)
Industry Position: 85.7% below the Medical Devices & Instruments median (#376 of 855)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
84GF Score
Get the complete analysis for SHSE:688656
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
